Overview
- Kevin Baillie says he told colleagues about medically supervised ketamine treatment for clinical depression during a “Vulnerability-Trust” exercise at Netflix’s Sendero Ranch in January 2026.
- Baillie alleges a company inquiry followed and that an investigator on March 18, 2026, questioned him in a way that suggested suspicion of recreational drug use.
- He was fired in April 2026 and court papers cite a company attorney as saying the ketamine therapy disclosure “factored into the termination,” with the suit claiming he was denied up to a year of severance.
- Baillie seeks a jury trial and damages for lost wages, emotional distress, compensatory and punitive relief and notes he previously earned about $1.1 million a year as Eyeline’s head of creative.
- The filing details alleged alcohol-friendly behavior by Eyeline leadership and frames the case as a test of how tech-studio HR and culture handle medical disclosures, with the lawsuit likely to drive scrutiny of internal investigatory and severance practices.